Cargando…

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency

Introduction: Setmelanotide is a melanocortin 4 receptor agonist indicated for chronic weight management in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. This analysis aimed to assess the timing o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clément, Karine, van den Akker, Erica L T, Gordon, Gregory, Yuan, Guojun, Kühnen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265764/ http://dx.doi.org/10.1210/jendso/bvab048.058

Ejemplares similares

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

MON-LB019 Setmelanotide (RM-493) Reduces Food Intake and Rapidly Induces Weight Loss in a Mouse Model of Alström Syndrome
por: Stephenson, Erin, et al.
Publicado: (2019)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

THU128 Transcription Factor ETV5 In POMC Neurons Regulate Energy And Glucose Homeostasis
por: Gahlot, Surbhi, et al.
Publicado: (2023)

SAT-596 POMC Expression in GABAergic Neurons Suppresses NPY Overexpression and Restores Food Intake in Obese Mice
por: Trotta, Milagros, et al.
Publicado: (2020)

Fatty Acids Modify the MicroRNA Content of Exosomes Released by Hypothalamic Astrocytes and the Response of POMC Neurons to These Exosomes
por: Collado-Pérez, Roberto, et al.
Publicado: (2021)

FRI031 A Novel Strategy To Detect Leptin Receptor (Lepr, fa) Mutation In Obesity And Diabetic Animal Model (Zucker Rats)
por: Xu, Xinyun, et al.
Publicado: (2023)

LBODP109 Astrocytes Affect The Metabolism Of Proopiomelanocortin (pomc) Neurons Through The Release Of Exosomes That Are Modified In A Fatty Acid Specific Manner
por: Collado-Pérez, Roberto, et al.
Publicado: (2022)

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide
por: Wabitsch, Martin, et al.
Publicado: (2022)

SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation
por: Klee, Philippe, et al.
Publicado: (2020)

SAT-598 Shared Signaling Profile Between Human MRAPα-Induced Human MC4R Constitutive Activity and Obesity-Associated Human MC4R Constitutive Activity
por: Botha, Rikus, et al.
Publicado: (2020)

SUN-LB107 Functional Characterisation of Human Heterozygous Non-Synonymous MC3R Variants
por: Melvin, Audrey, et al.
Publicado: (2020)

Distinct Calcium Signaling for Wildtype, Loss-of-Function and Gain-of-Function Human MC4R Variants
por: Kumar, Shree S, et al.
Publicado: (2021)

RF12 | PSUN125 Lymphoma in Congenital Leptin Deficiency: Comorbidity or Adverse Effect?
por: Torchen, Laura, et al.
Publicado: (2022)

OR04-01 MRAP2 Regulates Energy Homeostasis by Promoting Primary Cilia Localization of MC4R
por: Bernard, Adelaide A, et al.
Publicado: (2020)

FRI048 Cardiometabolic Risk Markers In Children With Obesity And Variants In MC4R Pathway Related Genes
por: Salama, Mostafa, et al.
Publicado: (2023)

SAT654 Regulation Of The Melanocortin-4 Receptor (mc4r) By Attractin Like Protein 1 (alp1)
por: Buscaglia, Paul, et al.
Publicado: (2023)

OR07-01 Aberrant Expression Of Agouti Signaling Protein (ASIP) As A Cause of Monogenic Severe Childhood Obesity
por: Landgraf, Kathrin, et al.
Publicado: (2023)

Acquired Brain Injury-Induced Hyperphagia and Obesity, Successfully Treated With a GLP-1 Agonist
por: Ngu, Michael, et al.
Publicado: (2021)

OR12-3 Mice with MC4R Site Mutation (F51L) Develop Severe Obesity Independent of G(s)-alpha/cAMP Signaling
por: Metzger, Peter, et al.
Publicado: (2019)

FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity
por: Botero Suarez, Carlos S, et al.
Publicado: (2023)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

LBSUN131 Leptin Level, BMI And Genetics In Early Onset Obesity
por: Xu, Xu, et al.
Publicado: (2022)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

FRI046 Clinical Phenotyping Of Adults With Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2023)

SAT649 Org43553, The First Low-molecular-weight Agonist Of The Human Luteinizing Hormone Receptor Induces Leanness And Energy Expenditure In Mice
por: Lizneva, Daria, et al.
Publicado: (2023)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kkjvfaqrq0bdono4tgj6psuqqj